[
Abstract]
[
Full Text PDF] （in Japanese / 1251KB）
[Members Only And Two Factor Auth.] J.Jpn. Surg. Soc.. 79(9): 1110-1115, 1978
Report on the annual meeting
ADJUVANT CHEMOTHERAPY FOR BREAST CANCER
Since 1967, a controlled study on adjuvant chemotherapy has been carried out in a series of 551 breast cancer patients undergoing radical mastectomy for cure. The chemotherapy consisted of Mitomicin C (MMC) 30 mg given in 3 intravenous shots within 5 days postoperatively and/or Cyclophosphamide (CY) 10 g or more given in daily oral dosis of 100 mg for a prolonged period. A 5-year cancer free survival rate in patients with 1-3 positive nodes in the axilla (N 1-3) was 84.8% for the chemotherapy group and 49.8% for the control, showing a statistically significant difference. In those with negative node (N -) and with 4 or more positive nodes (N 4-) , there was no significant difference in prognosis between the treated and the control groups. A recurrence rate as to distant metastasis was significantly lower in the treated group than the control in N 1-3, while the locoregional recurrencerate showed no significant difference between the two groups. Combination chemotherapy with MMC and CY was more effective than single drug treatment.
Intra-arterial infusion chemotherapy has been made as a preoperative treatment for locally advanced breast cancer. After the treatment a marked regressive change was observed in primary lesion and in axillary and supraclavicular lymph node metastasis. This treatment has considerably improved the 5-year results.
To read the PDF file you will need Adobe Reader installed on your computer.